×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Amgen Statement on Analyst Comments Concerning Kyprolis Trial Data

THOUSAND OAKS, Calif. (Nov. 21, 2013) – The biotech analyst at Bank of America Merrill Lynch issued a misleading note this morning following a dinner meeting with Celgene management. In our follow up with Celgene, they acknowledged citing anecdotal reports from high volume multiple myeloma centers of cardiovascular (CV) events with Kyprolis, but also clarified that they made no representation of the event rates being any different than what is already included in the Kyprolis label. The Phase 3 Kyprolis trials are monitored and safety data are reviewed regularly by independent Data Monitoring Committees (DMCs). To date, the DMCs have not reported any specific safety concerns and have recommended continuing the Phase 3 studies. The Bank of America Merrill Lynch note incorrectly characterizes confidential information on event rates during the course of the ASPIRE study, which are not shared with Celgene as part of the supply agreement.  Our post-marketing reporting and on-going clinical trial data have not revealed any new safety concerns. We remain enthusiastic about our ongoing comprehensive Phase 3 global development program for Kyprolis across all lines of therapy to address unmet medical needs of multiple myeloma patients.

###

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)